Xiwen Ma
16 Papers
40 Citations
Xiwen Ma is an academic researcher. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Medicine. The author has an hindex of 3, co-authored 16 publications.
Chat about Author
Papers
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
Nagesh Kalakonda,Marie Maerevoet,Federica Cavallo,George A Follows,Andre Goy,Joost S.P. Vermaat,Olivier Casasnovas,Nada Hamad,Josée M. Zijlstra,Sameer Bakhshi,Reda Bouabdallah,Sylvain Choquet,Ronit Gurion,Brian T. Hill,Ulrich Jaeger,Juan-Manuel Sancho,Michael W. Schuster,Catherine Thieblemont,Fatima De la Cruz,Miklos Egyed,Sourav Mishra,Fritz Offner,Theodoros P. Vassilakopoulos,Krzysztof Warzocha,Daniel McCarthy,Xiwen Ma,Kelly Corona,Jean Richard Saint-Martin,Hua Chang,Yosef Landesman,Anita Joshi,Hongwei Wang,Jatin P. Shah,Sharon Shacham,Michael Kauffman,Eric Van Den Neste,Miguel Canales +36 more
TL;DR: Single-drug oral selinexor induced durable responses and had a manageable adverse events profile in patients with relapsed or refractory DLBCL who received at least two lines of previous chemoimmunotherapy, and could be considered a new oral, non-cytotoxic treatment option in this setting.
288
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
Robert F. Cornell,Parameswaran Hari,Shijie Tang,Noa Biran,Natalie S. Callander,Ajai Chari,Saurabh Chhabra,Mark A. Fiala,Zhubin Gahvari,Ujjawal H. Gandhi,Kelly N. Godby,Ridhi Gupta,Sundar Jagannath,Megan Jagosky,Yubin Kang,Ankit Kansagra,Michael Kauffman,Saranya Kodali,Shaji Kumar,Arjun Lakshman,Michaela Liedtke,Sagar Lonial,Xiwen Ma,Ehsan Malek,Joshua Mansour,Joshua Mansour,Elizabeth McGehee,Amarendra K. Neppalli,Barry Paul,Paul G. Richardson,Emma C. Scott,Sharon Shacham,Jatin P. Shah,David S. Siegel,Elvira Umyarova,Saad Z. Usmani,William Varnado,Ravi Vij,Luciano J. Costa +38 more
TL;DR: A ten year review of the sickle cell program in Muhimbili National Hospital, Tanzania and the World Health Organization and Health Action International's Measuring Medicine Price, Availability, Affordability and Price Component.
30
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
Marie Maerevoet,Josée M. Zijlstra,George A Follows,René-Olivier Casasnovas,J. S. P. Vermaat,Nagesh Kalakonda,Andre Goy,Sylvain Choquet,Eric Van Den Neste,Brian T. Hill,Catherine Thieblemont,Federica Cavallo,Fatima De la Cruz,John Kuruvilla,Nada Hamad,Ulrich Jaeger,Paolo Caimi,Ronit Gurion,Krzysztof Warzocha,Sameer Bakhshi,Juan-Manuel Sancho,Michael W. Schuster,Miklos Egyed,Fritz Offner,Theodoros P. Vassilakopoulos,Priyanka Samal,Matthew Ku,Xiwen Ma,Kelly Corona,Kamal Chamoun,Jatin P. Shah,Sharon Shacham,Michael Kauffman,Miguel Canales +33 more
TL;DR: The SADAL trial as mentioned in this paper evaluated single-agent oral selinexor in patients with RR DLBCL and demonstrated an overall response rate (ORR) of 29.1% with median duration of response (DOR) of 9.3 months.
A Phase 1 Clinical Trial of Oral Eltanexor in Patients with Relapsed or Refractory Multiple Myeloma.
Robert F. Cornell,Rachid Baz,Joshua Richter,Adriana C Rossi,Dan T. Vogl,Christine Chen,Chaim Shustik,Mariano J. Alvarez,Yao Shen,Thaddeus J. Unger,Osnat Ben-Shahar,Hongwei Wang,Erkan Baloglu,William Senapedis,Xiwen Ma,Yosef Landesman,Xiang Bai,Justin C Bader,Hongmei Xu,Tracey Marshall,Hua Chang,Christopher J. Walker,Jatin P. Shah,Sharon Shacham,Michael Kauffman,Craig C. Hofmeister +25 more
12
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies
Luciano J. Costa,Parameswaran Hari,Shaji Kumar,Shijie Tang,Ujjawal H. Gandhi,Jatin J. Shah,Sundar Jagannath,Ajai Chari,Arjun Lakshman,Sharon Shacham,Xiwen Ma,David S. Siegel,Noa Biran,Sagar Lonial,Paul G. Richardson,Michael Kauffman,Ehsan Malek,Kelly N. Godby,Mark A. Fiala,Saurabh Chhabra,Saad Z. Usmani,Natalie S. Callander,Yubin Kang,Amarendra K. Neppalli,Elvira Umyarova,Robert F. Cornell +25 more
TL;DR: This analysis suggests improved OS with Sd vs conventional care in patients with TCR-PE RRMM, and reports the outcomes of patients with RRMM after they became refractory to dara, in the retrospective MAMMOTH study.
12